{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:46:30Z","timestamp":1782510390461,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ucl.2026.03.012","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:26:56Z","timestamp":1779362816000},"page":"487-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic Considerations in the Management of Superficial Bladder Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Veerain K.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Wymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2026.03.012_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.012_bib2","article-title":"The real-world lifetime economic burden of urothelial carcinoma by stage at diagnosis","volume":"6","author":"Aly","year":"2020","journal-title":"Journal of Clincal Pathways"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.012_bib3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s41669-024-00512-8","article-title":"Economic impact of bladder cancer in the USA","volume":"8","author":"Clark","year":"2024","journal-title":"Pharmacoecon Open"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.012_bib4","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.EPI-19-1534","article-title":"Medical care costs associated with cancer survivorship in the United States","volume":"29","author":"Mariotto","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"10.1016\/j.ucl.2026.03.012_bib5","doi-asserted-by":"crossref","DOI":"10.1007\/s40273-014-0194-2","article-title":"The health economics of bladder cancer: an updated review of the published literature","volume":"32","author":"Yeung","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.012_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/MOU.0000000000000078","article-title":"The burden of bladder cancer care: direct and indirect costs","volume":"24","author":"Mossanen","year":"2014","journal-title":"Curr Opin Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.012_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic burden of bladder cancer across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.03.012_bib8","doi-asserted-by":"crossref","DOI":"10.2147\/CEOR.S398180","article-title":"Healthcare resource utilization and cost burden of BCG-treated non-muscle invasive bladder cancer patients in Germany: a retrospective claims analysis","volume":"15","author":"Quignot","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.012_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2019.12.004","article-title":"Effects of bladder cancer on UK healthcare costs and patient health-related quality of life: evidence from the BOXIT trial","volume":"18","author":"Cox","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.012_bib10","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.euo.2021.02.007","article-title":"Financial toxicity among patients with prostate, bladder, and kidney cancer: a systematic review and call to action","volume":"4","author":"Bhanvadia","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ucl.2026.03.012_bib11","unstructured":"Gupta VK, Cortese BD, Talwar R, Joyce DD. Patient financial burden in urologic cancer and cancer care. AUA Update Series, 2025, 44(29). American Urological Association."},{"issue":"11","key":"10.1016\/j.ucl.2026.03.012_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/tbm\/ibab091","article-title":"Financial toxicity in cancer care: origins, impact, and solutions","volume":"11","author":"Abrams","year":"2021","journal-title":"Transl Behav Med"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.012_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40271-016-0204-x","article-title":"A systematic review of financial toxicity among cancer survivors: we can\u2019t pay the Co-Pay","volume":"10","author":"Gordon","year":"2017","journal-title":"The Patient - Patient-Centered Outcomes Research"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.012_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw205","article-title":"Financial hardships experienced by cancer survivors: a systematic review","volume":"109","author":"Altice","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.012_bib15","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.juro.2017.10.049","article-title":"Financial toxicity among patients with bladder cancer: reasons for delay in care and effect on quality of life","volume":"199","author":"Casilla-Lennon","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.012_bib16","doi-asserted-by":"crossref","first-page":"76.e1-e7","DOI":"10.1016\/j.urolonc.2020.09.030","article-title":"A national cross-sectional survey of financial toxicity among bladder cancer patients","volume":"39","author":"Ehlers","year":"2021","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.012_bib17","first-page":"1703","article-title":"Financial toxicity and its associations with health-related quality of life among urologic cancer patients in an upper middle-income country","volume":"28","author":"Ting","year":"2020","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.012_bib18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MOU.0000000000001218","article-title":"Reducing financial toxicity in bladder cancer care","volume":"34","author":"Kurnot","year":"2024","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.ucl.2026.03.012_bib19","unstructured":"National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 2.2025, National Comprehensive Cancer Network, 2025, 1-11, 75-92. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf (Accessed 7 October 2025)."},{"issue":"4","key":"10.1016\/j.ucl.2026.03.012_bib20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.03.012_bib21","series-title":"EAU guidelines on Non\u2013muscle-invasive bladder cancer (Ta, T1, and CIS)","year":"2025"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.012_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2006.03.062","article-title":"Clinical model of lifetime cost of treating bladder cancer and associated complications","volume":"68","author":"Avritscher","year":"2006","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.012_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: what are the benefits and costs?","volume":"27","author":"Sievert","year":"2009","journal-title":"World J Urol"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.012_bib24","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-018-2550-x","article-title":"Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories","volume":"37","author":"Mossanen","year":"2019","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.012_bib25","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.012_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2013.03.117","article-title":"Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma","volume":"190","author":"Gayed","year":"2013","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.012_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.012_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2012.03.007","article-title":"Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy","volume":"188","author":"Grossman","year":"2012","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.012_bib29","first-page":"6682","article-title":"The cost-effectiveness of blue light cystoscopy in bladder cancer detection: united States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation","volume":"20","author":"Garfield","year":"2013","journal-title":"Can J Urol"},{"key":"10.1016\/j.ucl.2026.03.012_bib30","article-title":"Photodynamic diagnosis-guided transurethral resection of bladder tumour in participants with a first suspected diagnosis of Intermediate- or high-risk non\u2013muscle-invasive bladder cancer: cost-effectiveness analysis alongside a randomised controlled trial","volume":"53","author":"Yu","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.012_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ajur.2016.05.001","article-title":"Narrow band imaging for bladder cancer","volume":"3","author":"Hsueh","year":"2016","journal-title":"Asian J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.012_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/bju.16269","article-title":"Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer","volume":"133","author":"Vitug","year":"2024","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.012_bib33","article-title":"A cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration","volume":"85","author":"Al Hussein","year":"2015","journal-title":"Urology"},{"issue":"3 B","key":"10.1016\/j.ucl.2026.03.012_bib34","article-title":"Cost-effective treatment of low-risk carcinoma not invading bladder muscle","volume":"111","author":"Green","year":"2013","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.012_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000001023","article-title":"Cost-effectiveness of maintenance bacillus calmette-gu\u00e9rin for intermediate and high risk nonmuscle invasive bladder cancer","volume":"204","author":"Sharma","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.012_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.ucl.2026.03.012_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.28731","article-title":"Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer","volume":"120","author":"Bachir","year":"2014","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.012_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2023.04.005","article-title":"Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: a preliminary cost-effectiveness analysis","volume":"41","author":"Bukavina","year":"2023","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.012_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s40273-023-01273-8","article-title":"Cost-effectiveness and economic impact of bladder cancer management: an updated review of the literature","volume":"41","author":"Joyce","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.012_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.012_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.012_bib42","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive Non\u2013muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.012_bib43","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000001515","article-title":"Cost-effectiveness analysis of pembrolizumab for bacillus calmette-gu\u00e9rin-unresponsive carcinoma in situ of the bladder","volume":"205","author":"Wymer","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.012_bib44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2024.10.012","article-title":"Unmet need in non\u2013muscle-invasive bladder cancer failing bacillus calmette-gu\u00e9rin therapy: a systematic review and cost-effectiveness analyses from the International Bladder Cancer Group","volume":"8","author":"D\u2019Andrea","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.012_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2025.09.4137","article-title":"Cost-effectiveness analysis of treatments for bacillus calmette-gu\u00e9rin-unresponsive carcinoma in situ of the bladder","volume":"89","author":"Myers","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.03.012_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2024.02.033","article-title":"Cost-utility of initial management of high-grade T1 bladder cancer with intravesical BCG vs immediate radical cystectomy","volume":"187","author":"Huelster","year":"2024","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.012_bib47","article-title":"How does cost-effectiveness analysis inform health care decisions?","volume":"23","author":"Kim","year":"2021","journal-title":"AMA J Ethics"},{"key":"10.1016\/j.ucl.2026.03.012_bib48","series-title":"NICE health technology evaluations: the manual","year":"2022"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.012_bib51","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:56:15Z","timestamp":1782507375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0094014326000388"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.012","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Considerations in the Management of Superficial Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}